{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:12:29Z","timestamp":1783440749471,"version":"3.54.6"},"reference-count":79,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":210,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mucosalimmunology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mucosal Immunology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1038\/s41385-021-00388-5","type":"journal-article","created":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T13:02:46Z","timestamp":1615986166000},"page":"899-911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation"],"prefix":"10.1016","volume":"14","author":[{"given":"Pedram","family":"Shafiei-Jahani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doumet Georges","family":"Helou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P.","family":"Hurrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauriane","family":"Galle-Treger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob D.","family":"Painter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hooman","family":"Allayee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-9725","authenticated-orcid":false,"given":"Omid","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41385-021-00388-5_bib1","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.jaci.2007.09.029","article-title":"Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007","volume":"120","author":"National Asthma Education and Prevention Program","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthma-present in most, absent in many","volume":"15","author":"Fahy","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fmed.2017.00093","article-title":"The biology of eosinophils and their role in asthma","volume":"4","author":"McBrien","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1038\/s41385-021-00388-5_bib4","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/imr.12554","article-title":"Type two innate lymphoid cells: the Janus cells in health and disease","volume":"278","author":"Maazi","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1038\/s41385-021-00388-5_bib5","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s00424-017-1970-6","article-title":"Interleukin-13 increases pendrin abundance to the cell surface in bronchial NCI-H292 cells via Rho\/actin signaling","volume":"469","author":"Russo","year":"2017","journal-title":"Pflug. Arch."},{"key":"10.1038\/s41385-021-00388-5_bib6","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jaci.2019.10.037","article-title":"IL-13 and IL-4, but not IL-5 nor IL-17A, induce hyperresponsiveness in isolated human small airways","volume":"145","author":"Manson","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib7","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1126\/science.aan8546","article-title":"Pulmonary neuroendocrine cells amplify allergic asthma responses","volume":"360","author":"Sui","year":"2018","journal-title":"Science"},{"key":"10.1038\/s41385-021-00388-5_bib8","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3389\/fimmu.2018.02694","article-title":"Social networking of group two innate lymphoid cells in allergy and asthma","volume":"9","author":"Hurrell","year":"2018","journal-title":"Front Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ni.3049","article-title":"The immunology of asthma","volume":"16","author":"Lambrecht","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding asthma phenotypes, endotypes, and mechanisms of disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib11","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1513\/AnnalsATS.201506-377AW","article-title":"The role of type 2 inflammation in the pathogenesis of asthma exacerbations","volume":"12","author":"Dunican","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1038\/s41385-021-00388-5_bib12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1006\/jmbi.1999.2750","article-title":"1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen","volume":"289","author":"James","year":"1999","journal-title":"J. Mol. Biol."},{"key":"10.1038\/s41385-021-00388-5_bib13","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1182\/blood-2002-04-1093","article-title":"Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation","volume":"101","author":"Ratzinger","year":"2003","journal-title":"Blood"},{"key":"10.1038\/s41385-021-00388-5_bib14","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood.V100.5.1715.h81702001715_1715_1720","article-title":"Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab","volume":"100","author":"Buggins","year":"2002","journal-title":"Blood"},{"key":"10.1038\/s41385-021-00388-5_bib15","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/10428190500052156","article-title":"CD52 expression in T-cell large granular lymphocyte leukemia-implications for treatment with alemtuzumab","volume":"46","author":"Osuji","year":"2005","journal-title":"Leuk. Lymphoma"},{"key":"10.1038\/s41385-021-00388-5_bib16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","article-title":"Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H","volume":"22","author":"Ginaldi","year":"1998","journal-title":"Leuk. Res"},{"key":"10.1038\/s41385-021-00388-5_bib17","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2009-02-203075","article-title":"Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab","volume":"114","author":"Ambrose","year":"2009","journal-title":"Blood"},{"key":"10.1038\/s41385-021-00388-5_bib18","first-page":"148","article-title":"CD52 antigen may be a therapeutic target for eosinophilic rhinosinusitis","volume":"37","author":"Zhang","year":"2007","journal-title":"Ann. Clin. Lab Sci."},{"key":"10.1038\/s41385-021-00388-5_bib19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2141.2009.07606.x","article-title":"Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy","volume":"145","author":"Jiang","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1038\/s41385-021-00388-5_bib20","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3816\/CLM.2006.n.029","article-title":"CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders","volume":"6","author":"Santos","year":"2006","journal-title":"Clin. Lymphoma Myeloma"},{"key":"10.1038\/s41385-021-00388-5_bib21","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1158\/1078-0432.CCR-06-1275","article-title":"Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)","volume":"12","author":"Rodig","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1038\/s41385-021-00388-5_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/146532401753174098","article-title":"The CD52 antigen and development of the CAMPATH antibodies","volume":"3","author":"Hale","year":"2001","journal-title":"Cytotherapy"},{"key":"10.1038\/s41385-021-00388-5_bib23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1474-4422(17)30007-8","article-title":"Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study","volume":"16","author":"Kalincik","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1038\/s41385-021-00388-5_bib24","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1080\/10428194.2017.1285027","article-title":"Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia","volume":"58","author":"Vojdeman","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1038\/s41385-021-00388-5_bib25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/jjco\/hyw146","article-title":"Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia","volume":"47","author":"Ishizawa","year":"2017","journal-title":"Jpn J. Clin. Oncol."},{"key":"10.1038\/s41385-021-00388-5_bib26","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/07357900600981414","article-title":"Alemtuzumab in CLL and other lymphoid neoplasms","volume":"24","author":"Ravandi","year":"2006","journal-title":"Cancer Invest"},{"key":"10.1038\/s41385-021-00388-5_bib27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40262-017-0573-x","article-title":"Review of the clinical pharmacokinetics and pharmacodynamics of Alemtuzumab and its use in kidney transplantation","volume":"57","author":"van der Zwan","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1038\/s41385-021-00388-5_bib28","first-page":"CD010968","article-title":"Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis","volume":"11","author":"Zhang","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1038\/s41385-021-00388-5_bib29","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1212\/WNL.0000000000003319","article-title":"Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients","volume":"87","author":"Giovannoni","year":"2016","journal-title":"Neurology"},{"key":"10.1038\/s41385-021-00388-5_bib30","first-page":"CD011203","article-title":"Alemtuzumab for multiple sclerosis","volume":"4","author":"Riera","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1038\/s41385-021-00388-5_bib31","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/ejh.12825","article-title":"Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I\/II multicentre trial","volume":"98","author":"Al-Sawaf","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"10.1038\/s41385-021-00388-5_bib32","first-page":"232","article-title":"[Guidelines for alemtuzumab treatment in chronic lymphocytic leukaemia (CLL)]","volume":"58","author":"Smolej","year":"2012","journal-title":"Vnitr. Lek."},{"key":"10.1038\/s41385-021-00388-5_bib33","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1038\/sj.onc.1210380","article-title":"Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia","volume":"26","author":"Alinari","year":"2007","journal-title":"Oncogene"},{"key":"10.1038\/s41385-021-00388-5_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15649-3","article-title":"Genome-wide analysis highlights contribution of immune system pathways to the genetic architecture of asthma","volume":"11","author":"Han","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1038\/s41385-021-00388-5_bib35","doi-asserted-by":"crossref","DOI":"10.1186\/s12948-018-0092-9","article-title":"House dust mite-related respiratory allergies and probiotics: a narrative review","volume":"16","author":"Fassio","year":"2018","journal-title":"Clin. Mol. Allergy"},{"key":"10.1038\/s41385-021-00388-5_bib36","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.it.2011.06.006","article-title":"Orchestrating house dust mite-associated allergy in the lung","volume":"32","author":"Gregory","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib37","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jaci.2018.06.015","article-title":"Innate and adaptive immune responses to fungi in the airway","volume":"142","author":"Bartemes","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib38","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00281-018-0688-7","article-title":"The roles for innate lymphoid cells in the human immune system","volume":"40","author":"Mazzurana","year":"2018","journal-title":"Semin Immunopathol."},{"key":"10.1038\/s41385-021-00388-5_bib39","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.it.2020.03.002","article-title":"Helper-like innate lymphoid cells in humans and mice","volume":"41","author":"Guia","year":"2020","journal-title":"Trends Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib40","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jaci.2013.05.012","article-title":"IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction","volume":"132","author":"Barlow","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18601-7","article-title":"DR3 stimulation of adipose resident ILC2s ameliorates type 2 diabetes mellitus","volume":"11","author":"Shafiei-Jahani","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1038\/s41385-021-00388-5_bib42","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/nar\/29.7.1399","article-title":"The RAG proteins in V(D)J recombination: more than just a nuclease","volume":"29","author":"Sadofsky","year":"2001","journal-title":"Nucleic Acids Res"},{"key":"10.1038\/s41385-021-00388-5_bib43","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jaci.2006.07.037","article-title":"Exposure to Alternaria alternata in US homes is associated with asthma symptoms","volume":"118","author":"Salo","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib44","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jaci.2017.03.010","article-title":"Beta2 integrins rather than beta1 integrins mediate Alternaria-induced group 2 innate lymphoid cell trafficking to the lung","volume":"141","author":"Karta","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib45","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000356341","article-title":"Innate type 2 response to Alternaria extract enhances ryegrass-induced lung inflammation","volume":"163","author":"Kim","year":"2014","journal-title":"Int Arch. Allergy Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib46","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jaci.2019.10.035","article-title":"Autophagy is critical for group 2 innate lymphoid cell metabolic homeostasis and effector function","volume":"145","author":"Galle-Treger","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib47","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1016\/j.celrep.2019.11.102","article-title":"TNFR2 signaling enhances ILC2 survival, function, and induction of airway hyperreactivity","volume":"29","author":"Hurrell","year":"2019","journal-title":"Cell Rep."},{"key":"10.1038\/s41385-021-00388-5_bib48","doi-asserted-by":"crossref","first-page":"542818","DOI":"10.3389\/fimmu.2020.542818","article-title":"Distinct roles of LFA-1 and ICAM-1 on ILC2s control lung infiltration, effector functions, and development of airway hyperreactivity","volume":"11","author":"Hurrell","year":"2020","journal-title":"Front Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib49","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.immuni.2015.02.007","article-title":"ICOS:ICOS-ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity","volume":"42","author":"Maazi","year":"2015","journal-title":"Immunity"},{"key":"10.1038\/s41385-021-00388-5_bib50","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jaci.2017.04.043","article-title":"Activated plasmacytoid dendritic cells regulate type 2 innate lymphoid cell-mediated airway hyperreactivity","volume":"141","author":"Maazi","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13202","article-title":"Nicotinic acetylcholine receptor agonist attenuates ILC2-dependent airway hyperreactivity","volume":"7","author":"Galle-Treger","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1038\/s41385-021-00388-5_bib52","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jaci.2016.08.034","article-title":"Type 2 innate lymphoid cell suppression by regulatory T cells attenuates airway hyperreactivity and requires inducible T-cell costimulator-inducible T-cell costimulator ligand interaction","volume":"139","author":"Rigas","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib53","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.jaci.2015.09.033","article-title":"Lack of autophagy induces steroid-resistant airway inflammation","volume":"137","author":"Suzuki","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12931-016-0359-y","article-title":"CD4(+) and CD8(+) T cells play a central role in a HDM driven model of allergic asthma","volume":"17","author":"Raemdonck","year":"2016","journal-title":"Respir. Res"},{"key":"10.1038\/s41385-021-00388-5_bib55","doi-asserted-by":"crossref","first-page":"e86689","DOI":"10.1172\/jci.insight.86689","article-title":"Depletion of major pathogenic cells in asthma by targeting CRTh2","volume":"1","author":"Huang","year":"2016","journal-title":"JCI Insight"},{"key":"10.1038\/s41385-021-00388-5_bib56","first-page":"100899","article-title":"Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab","volume":"28","author":"Matsuno","year":"2019","journal-title":"Respir. Med Case Rep."},{"key":"10.1038\/s41385-021-00388-5_bib57","doi-asserted-by":"crossref","first-page":"3743048","DOI":"10.1155\/2017\/3743048","article-title":"Pathological roles of neutrophil-mediated inflammation in asthma and its potential for therapy as a target","volume":"2017","author":"Gao","year":"2017","journal-title":"J. Immunol. Res"},{"key":"10.1038\/s41385-021-00388-5_bib58","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.it.2017.07.003","article-title":"Neutrophilic inflammation in asthma and association with disease severity","volume":"38","author":"Ray","year":"2017","journal-title":"Trends Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib59","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3389\/fimmu.2019.00821","article-title":"Mast cells and their progenitors in allergic asthma","volume":"10","author":"Mendez-Enriquez","year":"2019","journal-title":"Front Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib60","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1586\/1744666X.2013.837260","article-title":"Clinical view on the importance of dendritic cells in asthma","volume":"9","author":"Gaurav","year":"2013","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib61","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3389\/fimmu.2017.00941","article-title":"Dendritic cell subsets in asthma: impaired tolerance or exaggerated inflammation?","volume":"8","author":"Vroman","year":"2017","journal-title":"Front Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib62","first-page":"31234","article-title":"IL-10 production by ILC2s requires Blimp-1 and cMaf, modulates cellular metabolism, and ameliorates airway hyperreactivity","volume":"20","author":"Howard","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib63","doi-asserted-by":"crossref","DOI":"10.1186\/s40413-016-0131-2","article-title":"Asthma heterogeneity and severity","volume":"9","author":"Carr","year":"2016","journal-title":"World Allergy Organ J."},{"key":"10.1038\/s41385-021-00388-5_bib64","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrneurol.2013.2","article-title":"Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS","volume":"9","author":"Wiendl","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1038\/s41385-021-00388-5_bib65","doi-asserted-by":"crossref","first-page":"16414","DOI":"10.3390\/ijms160716414","article-title":"Alemtuzumab in multiple sclerosis: mechanism of action and beyond","volume":"16","author":"Ruck","year":"2015","journal-title":"Int J. Mol. Sci."},{"key":"10.1038\/s41385-021-00388-5_bib66","doi-asserted-by":"crossref","first-page":"20200","DOI":"10.1073\/pnas.1313654110","article-title":"Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation","volume":"110","author":"Jones","year":"2013","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10.1038\/s41385-021-00388-5_bib67","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1084\/jem.20080072","article-title":"CD45 regulates retention, motility, and numbers of hematopoietic progenitors, and affects osteoclast remodeling of metaphyseal trabecules","volume":"205","author":"Shivtiel","year":"2008","journal-title":"J. Exp. Med"},{"key":"10.1038\/s41385-021-00388-5_bib68","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1146\/annurev.immunol.21.120601.140946","article-title":"CD45: a critical regulator of signaling thresholds in immune cells","volume":"21","author":"Hermiston","year":"2003","journal-title":"Annu Rev. Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib69","doi-asserted-by":"crossref","DOI":"10.1186\/s40413-016-0130-3","article-title":"Therapeutic interventions in severe asthma","volume":"9","author":"Canonica","year":"2016","journal-title":"World Allergy Organ J."},{"key":"10.1038\/s41385-021-00388-5_bib70","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaci.2012.07.027","article-title":"Novel targeted therapies for eosinophilic disorders","volume":"130","author":"Wechsler","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1038\/s41385-021-00388-5_bib71","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.clml.2012.09.018","article-title":"Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody","volume":"13","author":"Strati","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1038\/s41385-021-00388-5_bib72","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1756285614563522","article-title":"Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use","volume":"8","author":"Havrdova","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1038\/s41385-021-00388-5_bib73","doi-asserted-by":"crossref","first-page":"e0138123","DOI":"10.1371\/journal.pone.0138123","article-title":"Characterisation of a novel anti-CD52 antibody with improved efficacy and reduced immunogenicity","volume":"10","author":"Holgate","year":"2015","journal-title":"PLoS One"},{"key":"10.1038\/s41385-021-00388-5_bib74","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1432-1033.1991.tb15858.x","article-title":"Production and purification of recombinant human interleukin-5 from yeast and baculovirus expression systems","volume":"196","author":"Ingley","year":"1991","journal-title":"Eur. J. Biochem"},{"key":"10.1038\/s41385-021-00388-5_bib75","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1073\/pnas.92.11.5194","article-title":"Identification of receptor-binding domains on human interleukin 5 and design of an interleukin 5-derived receptor antagonist","volume":"92","author":"Tavernier","year":"1995","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10.1038\/s41385-021-00388-5_bib76","doi-asserted-by":"crossref","first-page":"e59599","DOI":"10.1371\/journal.pone.0059599","article-title":"Lack of PD-L1 expression by iNKT cells improves the course of influenza A infection","volume":"8","author":"Maazi","year":"2013","journal-title":"PLoS One"},{"key":"10.1038\/s41385-021-00388-5_bib77","doi-asserted-by":"crossref","first-page":"101549","DOI":"10.1016\/j.isci.2020.101549","article-title":"Type 2 innate lymphoid cells induce CNS demyelination in an HSV-IL-2 mouse model of multiple sclerosis","volume":"23","author":"Hirose","year":"2020","journal-title":"iScience"},{"key":"10.1038\/s41385-021-00388-5_bib78","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17813-1","article-title":"PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity","volume":"11","author":"Helou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1038\/s41385-021-00388-5_bib79","doi-asserted-by":"crossref","first-page":"1313676","DOI":"10.1080\/20010001.2017.1313676","article-title":"Guidelines for collection and processing of lungs from aged mice for histological studies","volume":"7","author":"Morton","year":"2017","journal-title":"Pathobiol. Aging Age Relat. Dis."}],"container-title":["Mucosal Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41385-021-00388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41385-021-00388-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193302192200188X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193302192200188X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41385-021-00388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:11:14Z","timestamp":1761829874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193302192200188X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S193302192200188X"],"URL":"https:\/\/doi.org\/10.1038\/s41385-021-00388-5","relation":{},"ISSN":["1933-0219"],"issn-type":[{"value":"1933-0219","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation","name":"articletitle","label":"Article Title"},{"value":"Mucosal Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41385-021-00388-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 \u00a9 Society for Mucosal Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}